Table 3.
Patient characteristics of gastric cancer
| Total | Success | Fail | p-value | |
|---|---|---|---|---|
| No. (%) | 21 (100) | 7 (33.3) | 14 (66.7) | |
| Age (yr), median (range) | 59 (34–83) | 54 (34–66) | 60 (37–83) | 0.156 |
| Sample type | ||||
| Ascites | 20 | 6 (30.0) | 14 (70.0) | 0.333 |
| Pleural effusion | 1 | 1 (100) | 0 | |
| Cytopathology | ||||
| Positive | 12 | 6 (50.0) | 6 (50.0) | 0.161 |
| Negative | 9 | 1 (11.1) | 8 (88.9) | |
| Tumor differentiation | ||||
| Moderate | 1 | 1 (100) | 0 | 0.333 |
| Poor | 20 | 6 (30.0) | 14 (70.0) | |
| HER2 expression | ||||
| Negative | 20 | 7 (35.0) | 13 (65.0) | > 0.99 |
| Positive | 1 | 0 | 1 (100) | |
| Prior lines of therapy | ||||
| 0 or 1 | 8 | 3 (37.5) | 5 (62.5) | > 0.99 |
| 2 or more | 13 | 4 (30.8) | 9 (69.2) | |
Values are presented as number (%) unless otherwise indicated. HER2, human epidermal growth factor receptor 2.